Table of Contents

doi : 10.1016/S0923-7534(25)00107-3

Volume 36, Issue 4, April 2025, Pages i-ii

خرید پکیج و مشاهده آنلاین مقاله

Editorial Board

doi : 10.1016/S0923-7534(25)00086-9

خرید پکیج و مشاهده آنلاین مقاله

“Biomarker analyses from randomized trials in clear cell renal cell carcinoma�

doi : 10.1016/j.annonc.2025.02.012

خرید پکیج و مشاهده آنلاین مقاله

Progression-free survival: a true endpoint in first-line treatment for classic Hodgkin Lymphoma?

doi : 10.1016/j.annonc.2025.02.004

خرید پکیج و مشاهده آنلاین مقاله

Unveiling targets and resistance in FGFR-altered cancers

doi : 10.1016/j.annonc.2025.01.002

خرید پکیج و مشاهده آنلاین مقاله

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia

doi : 10.1016/j.annonc.2025.01.022

خرید پکیج و مشاهده آنلاین مقاله

Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma

doi : 10.1016/j.annonc.2024.12.003

خرید پکیج و مشاهده آنلاین مقاله

Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial

doi : 10.1016/j.annonc.2024.12.008

خرید پکیج و مشاهده آنلاین مقاله

Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trials☆

doi : 10.1016/j.annonc.2024.12.009

خرید پکیج و مشاهده آنلاین مقاله

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)☆

doi : 10.1016/j.annonc.2024.12.010

خرید پکیج و مشاهده آنلاین مقاله

Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling

doi : 10.1016/j.annonc.2024.11.017

خرید پکیج و مشاهده آنلاین مقاله

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma

doi : 10.1016/j.annonc.2024.12.011

خرید پکیج و مشاهده آنلاین مقاله

Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy

doi : 10.1016/j.annonc.2024.12.004

خرید پکیج و مشاهده آنلاین مقاله

European cancer mortality predictions for the year 2025 with focus on breast cancer

doi : 10.1016/j.annonc.2025.01.014

خرید پکیج و مشاهده آنلاین مقاله

Comments on the study of correlation between progression-free and overall survival in patients with Hodgkin lymphoma

doi : 10.1016/j.annonc.2025.01.012

خرید پکیج و مشاهده آنلاین مقاله

Reply to the Letter to the Editor ‘Comments on the study of correlation between progression-free and overall survival in patients with Hodgkin lymphoma’ by Zeng et al.

doi : 10.1016/j.annonc.2025.01.013

خرید پکیج و مشاهده آنلاین مقاله

Corrigendum to “Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group�: [Ann Oncol 35 (2024) 588-606]

doi : 10.1016/j.annonc.2024.11.010

خرید پکیج و مشاهده آنلاین مقاله

Corrigendum to “582P Knowledge, attitude and practices of physicians in Pakistan towards onco-hypertension�: [Annals of Oncology 35 (2024) S1612]

doi : 10.1016/j.annonc.2024.12.012

خرید پکیج و مشاهده آنلاین مقاله